Hostname: page-component-76fb5796d-9pm4c Total loading time: 0 Render date: 2024-04-26T07:11:47.023Z Has data issue: false hasContentIssue false
  • English
  • Français

Multiple Sclerosis Treated with Antithymocyte Globulin — A Five Year Follow-Up

Published online by Cambridge University Press:  18 September 2015

L.F. Kastrukoff ,
D.R. McLean  and
T.A. McPherson
L.F. Kastrukoff
Affiliation:
Department of Medicine, Division of Neurology of the University of Alberta, Edmonton
D.R. McLean*
Affiliation:
Department of Medicine, Division of Neurology of the University of Alberta, Edmonton
T.A. McPherson
Affiliation:
Division of Oncology of the University of Alberta, Edmonton
*
Division of Neurology, Department of Medicine, 9-101 Clinical Sciences Building, University of Alberta, Edmonton, Alberta, Canada T6G 2G3.
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Multiple sclerosis patients treated with antithymocyte globulin (ATG) were re-evaluated after five years. No long term benefit was found. Notably, the group of patients with an elevated gamma globulin to total protein ration in their C.S.F. and who did particularly well after treatment with ATG also failed to show any long term benefit. Few long term detrimental effects of ATG immunosuppression were identified. The implications of the results are discussed as they relate to the use of immunosuppression in multiple sclerosis.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 5 , Issue 2 , May 1978 , pp. 175 - 178
Copyright
Copyright © Canadian Neurological Sciences Federation 1978

References

REFERENCES

Brendel, W. Land, W. Frick, E, and Roscher, R. (1969). The effect of xenogenic anti-lymphocyte serum in various stages of experimental allergic encephalomyelitis, Europ. Surg. Res. 1: 253–257.CrossRefGoogle Scholar
Brendel, W. (1971). The clinical use of ALG. Transplant Proc. 3: 280–286.Google ScholarPubMed
Brendel, W., Ring, J., and Seifert, J. (1975). Immunosuppressive treatment of multiple sclerosis with ALG and/or thoracic duct drainage. Neurology (Minneap.) 25: 490–491.Google ScholarPubMed
Cochran, W., Cox, G., (1957). Experimental Designs. Ed. 2 New York, John Wiley and Sons.Google Scholar
Kurtzke, J., (1965). Further notes on disability evaluation in multiple sclerosis with scale modifications. Neurology (Minneap.) 15: 654–661.CrossRefGoogle ScholarPubMed
Lance, E. et al. (1975). Intensive immunosuppression in multiple sclerosis. Neurology (Minneap.) 25: 490.Google ScholarPubMed
Lance, E. et al. (1975). Intensive immunosuppression in patients with Disseminated Sclerosis I. Clinical Response. Clin. Exp. Immunol. 21: 1–12.Google ScholarPubMed
Land, W., Frick, E., Roscher, R., (1969). Wirkung eines heterologen antilymphocytenserums auf die experimentelle allergische encephalomyelitis. Klin. Wschr 47: 633–640.CrossRefGoogle ScholarPubMed
Leiobowitz, S., Lenof, M., Kennedy, L., (1968). Anti-lymphocyte serum in the later stages of experimental allergic encephalomyelitis. Lancet 1: 569–570.CrossRefGoogle Scholar
Leiobowitz, S., Lenof, M., Kennedy, L., (1968). The effect of anti-lymphocyte serum on experimental allergic encephalomyelitis in the guinea pig. Clin. Exp. Immunol. 3: 753–760.Google Scholar
Pirofski, B., Reid, R., Bardana, E., (1971). Antithymocyte antisera therapy in non-surgical immunological disease. Transplant Proc. 3: 769–772.Google Scholar
Ring, J. et al. (1974). Intensive immunosuppression in the treatment of multiple sclerosis. Lancet (Sat. Nov. 9) 1093–1096.CrossRefGoogle ScholarPubMed
Ring, J. et al (1976). Pilot study with anti-lymphocyte globulin in the treatment of multiple sclerosis. Postgrad. Med. J. 52 (Supple. 5): 123–128.Google Scholar
Schumacher, G., Beebe, G., Kibler, R., (1965). Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann. N.Y. Acad. Sci. 122: 522–568.CrossRefGoogle Scholar
Seland, P., McPherson, T., Grace, M., Lamoureux, G., Blain, G., (1974). Evaluation of antithymocyte globulin in acute relapses of multiple sclerosis. Neurology (Minneap.) 24: 34–40.CrossRefGoogle ScholarPubMed
Trouillas, P., Chazot, G.. Aimard, G., et al, (1970). Traitment de la sclerose en plaques par le serum antilymphocytaire intrarachiden. Bases theriaques facilites d’utilisation. Rev. Neurol. 123: 65–72.Google Scholar
Walker, J., Hoehn, M., Kashiwagi, N., (1976). A trial of anti-lymphocyte globulin in the treatment of chronic progressive multiple sclerosis. J. of Neuro. Sci. 29: 303–309.CrossRefGoogle Scholar